Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Rising Doses of Ritobegron in Healthy Male Volunteers
NCT02259764Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2004
- Primary completion
- Sep 2004
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in overactive bladder (OAB) comparing KUC 7483 CL - single rising dose with Placebo (2 arms). Primary endpoints: Number of subjects with abnormal findings in physical examination, Number of subjects with abnormal changes in laboratory parameters and 4 more. Started Aug 2004; status: completed.
02
Drugs
ritobegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02259764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259764.